Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 27, 2012Tue, June 26, 2012Mon, June 25, 2012Sun, June 24, 2012Sat, June 23, 2012Fri, June 22, 2012Thu, June 21, 2012Wed, June 20, 2012Tue, June 19, 2012Mon, June 18, 2012Sun, June 17, 2012Sat, June 16, 2012Fri, June 15, 2012Thu, June 14, 2012Wed, June 13, 2012Tue, June 12, 2012Mon, June 11, 2012Sat, June 9, 2012Fri, June 8, 2012Critical Outcome Technologies Inc. Presenting at the 2012 BIO International Convention
Published in Health and Fitness on Friday, June 15th 2012 at 6:06 GMT by Market Wire
June 15, 2012 09:00 ET
Critical Outcome Technologies Inc. Presenting at the 2012 BIO International Convention
LONDON, ONTARIO--(Marketwire - June 15, 2012) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that Dr. Wayne Danter, President & CEO, will be presenting at the 2012 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, Ma. COTI's presentation on Monday June 18 will highlight the scientific merit and commercial potential of COTI-2.
"We are delighted to be presenting at the 2012 BIO International Convention and to be given the opportunity to share with the life science community the continued progress of our novel, targeted anti- cancer drug candidate, COTI-2," said Dr. Danter. "The most recent results suggest COTI-2 is a highly selective, orally effective and well tolerated drug candidate that is well positioned for clinical development." COTI is currently evaluating potential partners with an interest in moving this novel, targeted anti-cancer drug candidate through development and to the market in indications where significant unmet medical need exists.
During preclinical testing, COTI-2 has demonstrated greater selectivity, an improved safety profile and superior pharmacokinetics in comparison to other AKT targeted compounds. Over expression of AKT/AKT2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors with active AKT/AKT2 range from 20% to 100% depending on the cancer type. COTI-2 is the most advanced compound in COTI's pipeline discovered through CHEMSAS®, its proprietary artificial intelligence platform.
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit [ www.criticaloutcome.com ].
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
